MedPath

Safety and Immunological Responses after COVID-19 vaccination in Thai Pregnant Wome

Phase 4
Completed
Conditions
Pregnancy outcomes following COVID-19 pregnancy in Thai women
COVID-19, vaccination, pregnant, Thai
Registration Number
TCTR20210717002
Lead Sponsor
ational Research Council of Thailand (NRCT)
Brief Summary

Heterologous schedules of CoronaVac-BNT162b2 or ChAdOx1-BNT162b2 induced immunogenicity on-par with BNT162b2-BNT162b2 and may be considered as alternative schedules for primary series in pregnant women in mRNA-limited vaccine settings.

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Female
Target Recruitment
165
Inclusion Criteria

1. Singleton pregnancy
2. Alive, intrauterine pregnancy
3. Gestational age >12 weeks
4. Literacy in Thai
5. Thai language literacy
6. Able to use applications e.g. Google form, Line
7. Able to comply follow-up schedules
8. Willing to participate in the study

Exclusion Criteria

1. History of uterine bleeding >2 times in the current pregnancy
2. Having uterine bleeding on the enrollment day
3. History of or having pre-eclampsia, abnormal placental position, preterm labor, fetal growth restriction
4. History of cigarettes smoking, alcohol drinking, recreational drugs
5. Recent immunization in prior 14 days
6. Previous COVID-19 immunization
7. Detection of COVID-19 in prior 90 days
8. Blood transfusion in prior 90 days
9. History of severe drug hypersensitivity
10. Type 1, 2 diabetes mellitus
11. Hypertension
12. Having uncontrollable diseases
13. Immunocompromised conditions, including steroid use
14. Investigators' judgement

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Adverse events Delivery Descriptive statistics
Secondary Outcome Measures
NameTimeMethod
Antibody response Delivery Descriptive statistics
© Copyright 2025. All Rights Reserved by MedPath